Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
274.40
-1.99 (-0.72%)
At close: Sep 15, 2025, 4:00 PM EDT
274.59
+0.19 (0.07%)
After-hours: Sep 15, 2025, 7:33 PM EDT
Amgen Employees
Amgen had 28,000 employees as of December 31, 2024. The number of employees increased by 1,300 or 4.87% compared to the previous year.
Employees
28,000
Change (1Y)
1,300
Growth (1Y)
4.87%
Revenue / Employee
$1,247,036
Profits / Employee
$236,393
Market Cap
147.73B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28,000 | 1,300 | 4.87% |
Dec 31, 2023 | 26,700 | 1,500 | 5.95% |
Dec 31, 2022 | 25,200 | 1,000 | 4.13% |
Dec 31, 2021 | 24,200 | -100 | -0.41% |
Dec 31, 2020 | 24,300 | 900 | 3.85% |
Dec 31, 2019 | 23,400 | 1,900 | 8.84% |
Dec 31, 2018 | 21,500 | 700 | 3.37% |
Dec 31, 2017 | 20,800 | 1,600 | 8.33% |
Dec 31, 2016 | 19,200 | 1,300 | 7.26% |
Dec 31, 2015 | 17,900 | 0 | - |
Dec 31, 2014 | 17,900 | -2,100 | -10.50% |
Dec 31, 2013 | 20,000 | 2,000 | 11.11% |
Dec 31, 2012 | 18,000 | 200 | 1.12% |
Dec 31, 2011 | 17,800 | 400 | 2.30% |
Dec 31, 2010 | 17,400 | 200 | 1.16% |
Dec 31, 2009 | 17,200 | 300 | 1.78% |
Dec 31, 2008 | 16,900 | -600 | -3.43% |
Dec 31, 2007 | 17,500 | -2,600 | -12.94% |
Dec 31, 2006 | 20,100 | 3,600 | 21.82% |
Dec 31, 2005 | 16,500 | 2,100 | 14.58% |
Dec 31, 2004 | 14,400 | 1,500 | 11.63% |
Dec 31, 2003 | 12,900 | 2,800 | 27.72% |
Dec 31, 2002 | 10,100 | 2,400 | 31.17% |
Dec 31, 2001 | 7,700 | 400 | 5.48% |
Dec 31, 2000 | 7,300 | 900 | 14.06% |
Dec 31, 1999 | 6,400 | 900 | 16.36% |
Dec 31, 1998 | 5,500 | 192 | 3.62% |
Dec 31, 1997 | 5,308 | 662 | 14.25% |
Dec 31, 1996 | 4,646 | 600 | 14.83% |
Dec 31, 1995 | 4,046 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AMGN News
- 1 day ago - Amgen: Buy The Dip Opportunity - Seeking Alpha
- 5 days ago - US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says - Reuters
- 6 days ago - US FDA to step up enforcement of pharma ads, sends enforcement letters - Reuters
- 6 days ago - Amgen Inc. (AMGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 6 days ago - Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis - GlobeNewsWire
- 7 days ago - AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS - PRNewsWire
- 9 days ago - September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog - Seeking Alpha
- 11 days ago - AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE - PRNewsWire